share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股sec公告 ·  05/20 16:13
Moomoo AI 已提取核心信息
TC BioPharm (Holdings) PLC, a Scotland-based biopharmaceutical company, has announced in a Form 8-K filing with the SEC that it has potentially regained compliance with Nasdaq's minimum stockholders' equity requirement. The company was previously not in compliance due to its stockholders' equity falling below the required $2.5 million as of March 31, 2024. However, following a successful cash exercise of existing Series E warrants by certain holders, TC BioPharm received approximately $3.9 million before fees and expenses. This exercise resulted in the issuance of new Series F warrants, which could potentially bring the company's stockholders' equity above the Nasdaq threshold. The transaction was completed on May 8, 2024, and the company believes it now meets the Nasdaq Capital Market's listing requirements as of the date of the latest filing on May 20, 2024.
TC BioPharm (Holdings) PLC, a Scotland-based biopharmaceutical company, has announced in a Form 8-K filing with the SEC that it has potentially regained compliance with Nasdaq's minimum stockholders' equity requirement. The company was previously not in compliance due to its stockholders' equity falling below the required $2.5 million as of March 31, 2024. However, following a successful cash exercise of existing Series E warrants by certain holders, TC BioPharm received approximately $3.9 million before fees and expenses. This exercise resulted in the issuance of new Series F warrants, which could potentially bring the company's stockholders' equity above the Nasdaq threshold. The transaction was completed on May 8, 2024, and the company believes it now meets the Nasdaq Capital Market's listing requirements as of the date of the latest filing on May 20, 2024.
总部位于苏格兰的生物制药公司TC Biopharm(Holdings)PLC在向美国证券交易委员会提交的8-K表中宣布,它有可能重新遵守纳斯达克的最低股东权益要求。由于截至2024年3月31日,其股东权益降至所需的250万美元以下,该公司此前未遵守合规。但是,在某些持有人成功兑现现有的E系列认股权证之后,TC BioPharm在扣除费用和支出前获得了约390万美元。此次活动促成了新的F系列认股权证的发行,这有可能使公司的股东权益超过纳斯达克的门槛。该交易于2024年5月8日完成,该公司认为,截至2024年5月20日最新申请之日,该交易现已满足纳斯达克资本市场的上市要求。
总部位于苏格兰的生物制药公司TC Biopharm(Holdings)PLC在向美国证券交易委员会提交的8-K表中宣布,它有可能重新遵守纳斯达克的最低股东权益要求。由于截至2024年3月31日,其股东权益降至所需的250万美元以下,该公司此前未遵守合规。但是,在某些持有人成功兑现现有的E系列认股权证之后,TC BioPharm在扣除费用和支出前获得了约390万美元。此次活动促成了新的F系列认股权证的发行,这有可能使公司的股东权益超过纳斯达克的门槛。该交易于2024年5月8日完成,该公司认为,截至2024年5月20日最新申请之日,该交易现已满足纳斯达克资本市场的上市要求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息